Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101073642 | 10107364 | 2 | F | 20060406 | 20140305 | 20140424 | 20140930 | EXP | US-GSKPPD-2014GSK005954 | GLAXOSMITHKLINE | 64.26 | YR | M | Y | 0.00000 | 20140930 | N | MD | COUNTRY NOT SPECIFIED | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101073642 | 10107364 | 1 | PS | AVANDIA | ROSIGLITAZONE MALEATE | 1 | ORAL | AVANDIA WAS NOT LISTED AMONG THE PATIENTS RECORDS REVIEWED. | D | 21071 | TABLETS | ||||||||
| 101073642 | 10107364 | 2 | C | ASPIRIN. | ASPIRIN | 1 | ORAL | D | 0 | 81 | MG | ||||||||
| 101073642 | 10107364 | 3 | C | PLAVIX | CLOPIDOGREL BISULFATE | 1 | D | 0 | 75 | MG | |||||||||
| 101073642 | 10107364 | 4 | C | IMDUR | ISOSORBIDE MONONITRATE | 1 | ORAL | D | 0 | 30 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 101073642 | 10107364 | 1 | Diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 101073642 | 10107364 | HO |
| 101073642 | 10107364 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 101073642 | 10107364 | Cerebrovascular accident | |
| 101073642 | 10107364 | Myocardial infarction |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |